Article

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

Department of Medicine, Wilhelminenspital, Montleartstr. 37, 1160 Vienna, Austria.
The Oncologist (Impact Factor: 4.54). 01/2010; 15(1):6-25. DOI: 10.1634/theoncologist.2009-0203
Source: PubMed

ABSTRACT The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents thalidomide, bortezomib, and lenalidomide has expanded treatment options and has improved the outcome of patients with MM. Following the introduction of these agents in the relapsed/refractory setting, they are also undergoing investigation in the initial treatment of MM. A number of phase III trials have demonstrated the efficacy of novel agent combinations in the transplant and nontransplant settings, and based on these results standard induction regimens are being challenged and replaced. In the transplant setting, a number of newer induction regimens are now available that have been shown to be superior to the vincristine, doxorubicin, and dexamethasone regimen. Similarly, in the front-line treatment of patients not eligible for transplantation, regimens incorporating novel agents have been found to be superior to the traditional melphalan plus prednisone regimen. Importantly, some of the novel agents appear to be active in patients with high-risk disease, such as adverse cytogenetic features, and certain comorbidities, such as renal impairment. This review presents an overview of the most recent data with these novel agents and summarizes European treatment practices incorporating the novel agents.

Download full-text

Full-text

Available from: Meral Beksac, Jun 27, 2015
0 Followers
 · 
159 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: One of the greatest challenges in multiple myeloma (MM) treatment is to overcome drug resistance. Many pathways are involved including Notch signaling. Notch receptors are expressed by MM cells and Notch ligand Dll1 is present on bone marrow (BM) stromal cells. In this study, we demonstrate that Dll1 can activate Notch signaling mostly through Notch2 receptor and can contribute to drug resistance to bortezomib, both in murine and human MM cells. Blocking the Notch pathway by DAPT (gamma secretase inhibitor) could reverse this effect and increased sensitivity to bortezomib. We describe the upregulation of CYP1A1, a Cytochrome P450 enzyme involved in drug metabolism, as a possible mechanism of Dll1/Notch induced bortezomib resistance. This was confirmed by inhibition experiments using α-Naphthoflavone or CYP1A1-siRNA that resulted in an increased sensitivity to bortezomib. In addition, in vivo data showed that combination treatment of DAPT with bortezomib was able to increase bortezomib sensitivity and prolonged overall survival in the 5T33MM mouse model. Our data provide a potential strategy to overcome bortezomib resistance by Notch inhibition in MM therapy.
    Biochemical and Biophysical Research Communications 10/2012; 428(4). DOI:10.1016/j.bbrc.2012.10.071 · 2.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We will recall briefly the thermoelectric data on single crystals of Bi, Sb, Te, Se alloys grown by the travelling heater method. The crystalline quality of these single crystals will be characterized by X-ray topography (Synchrotron Beam). The observed dislocations are parallel to the cleavage planes with a density of 10<sup>5</sup> cm<sup>-2</sup>. Other defects in relationship with the growth are also observed. The composition homogeneity of the crystal is analysed by thermal probe. The quality of the single crystals permits us to perform experiments on diffusion. We recall the results for the anisotropic diffusion coefficient of selenium in bismuth telluride along the solidus line and we propose a mechanism of atomic diffusion. An important increase of the growth rate up to 40 mm per day gives materials with an excellent figure of merit (Zp=3.10<sup>-3</sup> K<sup>-1</sup>, Zn=3.10 <sup>-1</sup> K<sup>-1</sup>)
    Thermoelectrics, 1998. Proceedings ICT 98. XVII International Conference on; 06/1998
  • Blood 03/2010; 115(12):2332-3. DOI:10.1182/blood-2010-02-268730 · 9.78 Impact Factor